SRRK Quote, Financials, Valuation and Earnings

Mersana Therapeutics, Inc. has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of -68.54%. Scholar Rock Holding Corp.'s return on equity of -142.69% beat Mersana Therapeutics, Inc.'s return on equity of -533.43%.

Scholar Rock Holding Corp. has a consensus price target of $47.92, signalling upside risk potential of 4.92%. On the other hand Mersana Therapeutics, Inc. has an analysts' consensus of $33.20 which suggests that it could grow by 14.19%. Given that Mersana Therapeutics, Inc. has higher upside potential than Scholar Rock Holding Corp., analysts believe Mersana Therapeutics, Inc. is more attractive than Scholar Rock Holding Corp..

Scholar Rock Holding Corp. has a beta of 0.608, which suggesting that the stock is 39.233% less volatile than S&P 500. In comparison Mersana Therapeutics, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.856%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. Mersana Therapeutics, Inc. pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are smaller than Mersana Therapeutics, Inc. quarterly revenues of $11M. Scholar Rock Holding Corp.'s net income of -$102.2M is lower than Mersana Therapeutics, Inc.'s net income of -$7.5M. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while Mersana Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus 56.52x for Mersana Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of -255.85%. Scholar Rock Holding Corp.'s return on equity of -142.69% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Scholar Rock Holding Corp. has a consensus price target of $47.92, signalling upside risk potential of 4.92%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Scholar Rock Holding Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Scholar Rock Holding Corp. is more attractive than NovaBay Pharmaceuticals, Inc..

Scholar Rock Holding Corp. has a beta of 0.608, which suggesting that the stock is 39.233% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Scholar Rock Holding Corp.'s net income of -$102.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of -27.41%. Scholar Rock Holding Corp.'s return on equity of -142.69% beat Twist Bioscience Corp.'s return on equity of -16.74%.

Scholar Rock Holding Corp. has a consensus price target of $47.92, signalling upside risk potential of 4.92%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $35.88 which suggests that it could grow by 8.55%. Given that Twist Bioscience Corp. has higher upside potential than Scholar Rock Holding Corp., analysts believe Twist Bioscience Corp. is more attractive than Scholar Rock Holding Corp..

Scholar Rock Holding Corp. has a beta of 0.608, which suggesting that the stock is 39.233% less volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.242, suggesting its more volatile than the S&P 500 by 124.157%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are smaller than Twist Bioscience Corp. quarterly revenues of $99M. Scholar Rock Holding Corp.'s net income of -$102.2M is lower than Twist Bioscience Corp.'s net income of -$27.1M. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus 5.27x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.